India's Shilpa Medicare gains on approval for OERIS
11/09/2026 10:44
BUZZ-India's Shilpa Medicare gains on approval for OERIS ** Shares of India's Shilpa Medicare SHME.NS rise 2.2% to 960.75 rupees
** Drugmaker says it received final approval from Subject Expert Committee (SEC) under India's Central Drugs Standard Control Organization (CDSCO) for marketing authorization of OERIS, an extended-release ondansetron injection
** Adds OERIS is designed to provide antiemetic protection for up to 120 hours following a single administration
** Co says the product will be launched in India and has patent protection in the country until 2039
** Stock up nearly three-fold YTD
(Reporting by Payel Das in Bengaluru)
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026